Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase

Molecular Cell

Volumn 25, Issue 3, 2007, Pages 473-481

  Kubicek, Stefan ^a   O'Sullivan, Roderick J ^a   August, E Michael ^b   Hickey, Eugene R ^b   Zhang, Qiang ^b   Teodoro, Miguel L ^b   Rea, Stephen ^a   Mechtler, Karl ^a   Kowalski, Jennifer A ^b   Homon, Carol Ann ^b   Kelly, Terence A ^b   Jenuwein, Thomas ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

DNA

Indexed keywords

AMINE; BIX 01294; DIAZEPINE DERIVATIVE; HISTONE H3; HISTONE LYSINE METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE G9A; LYSINE; METHYLTRANSFERASE INHIBITOR; PROTEIN H3K9ME2; QUINAZOLINE DERIVATIVE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CHROMATIN IMMUNOPRECIPITATION; EMBRYONIC STEM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION REGULATION; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN METHYLATION;

ANIMALS; AZEPINES; CELL LINE; ENZYME INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LYSINE; METHYLATION; MICE; PROMOTER REGIONS (GENETICS); QUINAZOLINES;

MAMMALIA;

EID: 33846783261     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2007.01.017     Document Type: Article

References (31)

1. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6 (2006) 107-116
2. Cheng D., Yadav N., King R.W., Swanson M.S., Weinstein E.J., and Bedford M.T. Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem. 279 (2004) 23892-23899
3. Cheng J.C., Yoo C.B., Weisenberger D.J., Chuang J., Wozniak C., Liang G., Marquez V.E., Greer S., Orntoft T.F., Thykjaer T., and Jones P.A. Preferential response of cancer cells to zebularine. Cancer Cell 6 (2004) 151-158
4. Feldman N., Gerson A., Fang J., Li E., Zhang Y., Shinkai Y., Cedar H., and Bergman Y. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat. Cell Biol. 8 (2006) 188-194
5. Garcia-Manero G., and Issa J.P. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 23 (2005) 635-642
6. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., Grever M., Galm O., Dauses T., Karp J.E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66 (2006) 6361-6369
7. Greiner D., Bonaldi T., Eskeland R., Roemer E., and Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 1 (2005) 143-145
8. Hochedlinger K., Rideout W.M., Kyba M., Daley G.Q., Blelloch R., and Jaenisch R. Nuclear transplantation, embryonic stem cells and the potential for cell therapy. Hematol. J. 5 Suppl 3 (2004) S114-S117
9. Huang S. Histone methyltransferases, diet nutrients and tumour suppressors. Nat. Rev. Cancer 2 (2002) 469-476
10. Jenuwein T. The epigenetic magic of histone lysine methylation. FEBS J. 273 (2006) 3121-3135
11. Kim K.C., Geng L., and Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 63 (2003) 7619-7623
12. Lachner M., Sengupta R., Schotta G., and Jenuwein T. Trilogies of histone lysine methylation as epigenetic landmarks of the eukaryotic genome. Cold Spring Harb. Symp. Quant. Biol. 69 (2004) 209-218
13. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv. Cancer Res. 91 (2004) 137-168
14. Martens J.H., O'Sullivan R.J., Braunschweig U., Opravil S., Radolf M., Steinlein P., and Jenuwein T. The profile of repeat-associated histone lysine methylation states in the mouse epigenome. EMBO J. 24 (2005) 800-812
15. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., and Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 66 (2006) 3541-3549
16. Nawrocka W. Syntheses and pharmacological properties of new 2-aminobenzimidazole derivatives. Boll. Chim. Farm. 135 (1996) 18-23
17. Nishioka K., Chuikov S., Sarma K., Erdjument-Bromage H., Allis C.D., Tempst P., and Reinberg D. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 16 (2002) 479-489
18. Ogawa H., Ishiguro K., Gaubatz S., Livingston D.M., and Nakatani Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 296 (2002) 1132-1136
19. Rea S., Eisenhaber F., O'Carroll D., Strahl B.D., Sun Z.W., Schmid M., Opravil S., Mechtler K., Ponting C.P., Allis C.D., and Jenuwein T. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406 (2000) 593-599
20. Roopra A., Qazi R., Schoenike B., Daley T.J., and Morrison J.F. Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. Mol. Cell 14 (2004) 727-738
21. Schneider R., Bannister A.J., and Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem. Sci. 27 (2002) 396-402
22. Strahl B.D., Briggs S.D., Brame C.J., Caldwell J.A., Koh S.S., Ma H., Cook R.G., Shabanowitz J., Hunt D.F., Stallcup M.R., and Allis C.D. Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr. Biol. 11 (2001) 996-1000
23. Tachibana M., Sugimoto K., Nozaki M., Ueda J., Ohta T., Ohki M., Fukuda M., Takeda N., Niida H., Kato H., and Shinkai Y. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16 (2002) 1779-1791
24. Tachibana M., Ueda J., Fukuda M., Takeda N., Ohta T., Iwanari H., Sakihama T., Kodama T., Hamakubo T., and Shinkai Y. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev. 19 (2005) 815-826
25. Trojer P., and Reinberg D. Histone lysine demethylases and their impact on epigenetics. Cell 125 (2006) 213-217
26. Wang H., Cao R., Xia L., Erdjument-Bromage H., Borchers C., Tempst P., and Zhang Y. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol. Cell 8 (2001) 1207-1217
27. Wang H., An W., Cao R., Xia L., Erdjument-Bromage H., Chatton B., Tempst P., Roeder R.G., and Zhang Y. mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol. Cell 12 (2003) 475-487
28. Weidinger G. Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. Arzneimittelforschung 45 (1995) 1166-1171
29. Xin Z., Tachibana M., Guggiari M., Heard E., Shinkai Y., and Wagstaff J. Role of histone methyltransferase G9a in CpG methylation of the Prader-Willi syndrome imprinting center. J. Biol. Chem. 278 (2003) 14996-15000
30. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5 (2006) 37-50
31. Zhang X., Yang Z., Khan S.I., Horton J.R., Tamaru H., Selker E.U., and Cheng X. Structural basis for the product specificity of histone lysine methyltransferases. Mol. Cell 12 (2003) 177-185